Loading...
Market
Mounjaro surpasses Ozempic in European diabetes treatment market share by end of 2025?
2
Novo Nordisk•Ozempic•European Medicines Agency•EMA•Harvard University•Eli Lilly•Mounjaro•Britons•Wegovy
Resolution / Starting Odds
Yes • 50%
No • 50%
Market share reports from pharmaceutical market analysis firms
Story
Novo Nordisk's Ozempic Label Update Approved by EMA for Risk Reduction of Kidney Disease-Related Events Amid Vision Loss Study
Dec 13, 2024, 01:46 PM
Novo Nordisk's diabetes drug Ozempic has received a positive opinion from the European Medicines Agency (EMA) to update its label, which will now reflect the drug's potential to reduce the risk of kidney disease-related events. This approval follows a study that found a small number of patients experienced vision loss linked to Ozempic, corroborating previous research from Harvard University. Concurrently, Eli Lilly's Mounjaro is gaining popularity among Britons seeking obesity treatments, surpassing Novo Nordisk's Wegovy in preference. The recent findings suggest that while Ozempic may offer significant benefits for weight management and diabetes, its association with rare vision loss raises important safety considerations for patients and healthcare providers alike.
View original story
Similar markets
Novo Nordisk • 25%
Pfizer • 25%
Eli Lilly • 25%
Other • 25%
Rejected by FDA • 25%
Pending approval • 25%
FDA approved and in market • 25%
Withdrawn by manufacturer • 25%
Novo Nordisk • 25%
EMS • 25%
Sanofi • 25%
Other • 25%
Other regulatory actions • 25%
No action taken • 25%
Safety label update • 25%
Product recall • 25%
Neutral • 25%
Somewhat positive • 25%
Highly positive • 25%
Negative • 25%
Novo Nordisk > 60% • 25%
Eli Lilly > 60% • 25%
Novo Nordisk 40-60% • 25%
Eli Lilly 40-60% • 25%
